Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

Telangiectasia, Hereditary Hemorrhagic Clinical Trial

Official title:

Investigation of Coagulation Parameters in Hereditary Haemorrhagic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00230659
• Other study ID #: IC/CLS6
• Status: Completed
• Start date: August 2004
• Est. completion date: July 2008

Study information

• Verified date: September 2023
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We will address coagulation parameters in hereditary haemorrhagic telangiectasia (HHT) compared to controls.

Description:

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.

We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.

We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: July 2008
• Est. primary completion date: July 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with HHT and normal controls

Exclusion Criteria:

• Previous thrombosis, recent ill health

Related Conditions & MeSH terms

• Telangiectasia, Hereditary Hemorrhagic
• Telangiectasis

Intervention

Other:
• Blood sample to be taken.
Blood sample to be taken.

Locations

Country	Name	City	State
United Kingdom	Imperial College Hammersmith Campus	London

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	Hammersmith Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, Shovlin CL. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with — View Citation

Shovlin CL, Chamali B, Santhirapala V, Livesey JA, Angus G, Manning R, Laffan MA, Meek J, Tighe HC, Jackson JE. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron defi — View Citation

Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007 Nov;98(5):1031-9. — View Citation